# Sequencing Abiraterone and Enzalutamide in mCRPC

> **NCT02125357** · PHASE2 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 202 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02125357
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2020-02-04
- **Final completion:** 2020-02-04
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125357, "Sequencing Abiraterone and Enzalutamide in mCRPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02125357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*